Live feed08:00:00·3dPRReleaseKyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 WeeksKYTX· Kyverna Therapeutics Inc.Health CareOriginal source
